SCHEMBL2298959

SCHEMBL2298959

O=C(O)CCCNC(=O)c1cc(-c2ccc(NC(=O)Nc3ccccc3F)cc2)no1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
RAB9A P51151 2/20 0.53
KDM4E B2RXH2 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
RXFP1 Q9HBX9 1/20 0.53
CSGALNACT1 Q8TDX6 13/20 0.52
ALDH1A1 P00352 1/20 0.52
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
NPC1 O15118 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
PKM P14618 1/20 0.44
KIT P10721 1/20 0.44
KDR P35968 1/20 0.44
FLT3 P36888 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2293643 0.90 SMN1; SMN2 (0.58) MEN1KMT2ARAB9AKDM4ESMN1; SMN2
SCHEMBL2297268 0.84 CSGALNACT1 (0.61) MEN1KMT2AKDM4ESMN1; SMN2CSGALNACT1
SCHEMBL2297791 0.83 RAB9A (0.58) MEN1KMT2ARAB9AKDM4ESMN1; SMN2
SCHEMBL19747788 0.82 MEN1 (0.53) MEN1KMT2ARAB9AKDM4ESMN1; SMN2
SCHEMBL2300930 0.80 MEN1 (0.56) MEN1KMT2ARAB9AKDM4ESMN1; SMN2
SCHEMBL2296876 0.80 CSGALNACT1 (0.60) MEN1KMT2ARAB9AKDM4ESMN1; SMN2
SCHEMBL2296895 0.80 CSGALNACT1 (0.60) MEN1KMT2ARAB9AKDM4ESMN1; SMN2
SCHEMBL2294524 0.79 CSGALNACT1 (0.59) MEN1KMT2ARAB9AKDM4ESMN1; SMN2
SCHEMBL17652562 0.78 HDAC1 (0.54) MEN1KMT2ARAB9AKDM4ESMN1; SMN2
SCHEMBL2298940 0.78 CSGALNACT1 (0.82) CSGALNACT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US claimed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US claimed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO claimed
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US disclosed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US disclosed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, DLAT MEN1 4530/4885KMT2A 1450/4885RAB9A 3753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.